Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease

Journal of Human Hypertension
Vasilios G AthyrosGREACE Study Collaborative Group

Abstract

We assessed the 'synergy' of statins and angiotensin-converting enzyme inhibitors (ACEI) in reducing vascular events in patients with coronary heart disease (CHD). The GREek Atorvastatin and CHD Evaluation (GREACE) Study, suggested that aggressive reduction of low density lipoprotein cholesterol to 2.59 mmol/l (<100 mg/dl) significantly reduces morbidity and mortality in CHD patients, in comparison to undertreated patients. In this post hoc analysis of GREACE the patients (n=1600) were divided into four groups according to long-term treatment: Group A (n=460 statin+ACEI), B (n=420; statin, no ACEI), C (n=371;no statin, on ACEI), and D (n=349; no statin, no ACEI). Analysis of variance was used to assess differences in the relative risk reduction (RRR) in 'all events' (primary end point) between groups. During the 3-year follow-up there were 292 cardiovascular events; 45 (10% of patients) in group A, 61 (14.5%) in group B, 91 in group C (24.5%) and 95 events in group D (27%). The RRR (95% confidence interval (CI) in the primary end point in group A was 31%, (95% CI -48 to -6%, P=0.01) in comparison to group B, 59% (95% CI -72 to -48%, P<0.0001) to group C and 63% (95% CI -74 to -51%, P<0.0001) to group D. There was no significant...Continue Reading

References

Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Jul 13, 1995·The American Journal of Cardiology·H W EichstädtG Weidinger
Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Jan 25, 2002·Annals of the New York Academy of Sciences·R J GryglewskiJ Madej
May 7, 2002·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·F YoussefG Hamilton
Oct 9, 2002·Angiology·Moses Elisaf, Dimitri P Mikhailidis
Mar 29, 2003·Current Medical Research and Opinion·Athanasios G KontopoulosHarisios Boudoulas
Jul 10, 2003·Journal of the American College of Cardiology·L Brent MitchellUNKNOWN AVID Investigators
Sep 10, 2003·Cleveland Clinic Journal of Medicine·Paul SchoenhagenE Murat Tuzcu
Oct 8, 2003·Current Pharmaceutical Design·Haralampos J MilionisDimitri P Mikhailidis
Oct 8, 2003·Current Pharmaceutical Design·E S GanotakisD P Mikhailidis
Nov 5, 2003·Current Medical Research and Opinion·Stavroula TsiaraDimitri P Mikhailidis
Dec 12, 2003·Angiology·Vasilios G AthyrosUNKNOWN GREACE Study Collaborative Group
Mar 26, 2004·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Vasilios G AthyrosUNKNOWN GREACE Study Collaborative Group
Nov 9, 2004·Atherosclerosis. Supplements·T R PedersenUNKNOWN Scandinavian Simvastatin Survival Study Group

❮ Previous
Next ❯

Citations

Jan 9, 2007·Cardiovascular and Interventional Radiology·Anthony S Wierzbicki
Aug 24, 2007·Lipids·Vasilios G AthyrosUNKNOWN GREACE Study Collaborative Group
Nov 2, 2006·Current Diabetes Reports·Tamara DarsowDavid Maggs
May 24, 2007·Current Hypertension Reports·Haralampos J MilionisDimitri P Mikhailidis
Jun 27, 2009·Current Medical Research and Opinion·Mariusz StepienJacek Rysz
Jul 1, 2011·Current Medical Research and Opinion·Vassilios G AthyrosUNKNOWN Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group
Jan 10, 2016·International Journal of Cardiology·Juan TamargoValentín Fuster
Apr 26, 2013·The Journal of Clinical Hypertension·Alexandros BriasoulisFranz H Messerli
Jun 13, 2015·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Branislava Ivanovic, Marijana Tadic
Jul 15, 2006·Annals of Vascular Surgery·Mohamad E AlnaebGeorge Hamilton
Oct 12, 2007·Expert Opinion on Pharmacotherapy·Vasilios G AthyrosAsterios Karagiannis
Mar 10, 2015·Expert Opinion on Pharmacotherapy·Kwang Kon KohWook-Jin Chung
May 13, 2006·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·K I ParaskevasD P Mikhailidis
Jun 4, 2016·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Michel E BertrandJean-Jacques Mourad
Sep 30, 2005·Angiology·Kosmas I ParaskevasChristos D Liapis
Jun 21, 2005·Journal of Cardiovascular Pharmacology and Therapeutics·Stella S DaskalopoulouDimitri P Mikhailidis
May 17, 2006·Journal of Cardiovascular Pharmacology and Therapeutics·Sofia G TsouliMoses S Elisaf
Nov 7, 2007·Journal of Hypertension·José W A van der HoornJ Wouter Jukema
Mar 3, 2006·Journal of Human Hypertension·H J MilionisD P Mikhailidis
Sep 27, 2005·Expert Review of Cardiovascular Therapy·Harold BaysMichael Davidson
May 26, 2010·Expert Opinion on Pharmacotherapy·Michael S KostapanosMoses S Elisaf
Dec 31, 2011·The Open Cardiovascular Medicine Journal·Vasilios G AthyrosAsterios Karagiannis
Jun 27, 2009·The Open Cardiovascular Medicine Journal·Asterios KaragiannisDimitri P Mikhailidis
Feb 9, 2021·Wiener klinische Wochenschrift·Ivan KrečakMarko Lucijanić
May 29, 2021·Journal of Separation Science·Nataliia ShulyakLiliya Logoyda
Aug 17, 2021·ACS Applied Materials & Interfaces·Laura Ruiz-CantuRicky D Wildman
Dec 29, 2016·Current Opinion in Lipidology·Niki KatsikiCostas Tsioufis

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.